Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo

Z Feng, S Xu, M Liu, YX Zeng, T Kang - Cancer letters, 2010 - Elsevier
Z Feng, S Xu, M Liu, YX Zeng, T Kang
Cancer letters, 2010Elsevier
Nasopharyngeal carcinoma (NPC) is a malignant tumor. This type of carcinoma has a low 5-
year patient survival rate. Thus, there is a need for improved therapeutics. We determined
that the Chk1 inhibitor Gö6976 enhanced the sensitivity of CNE1 and CNE2 cells to ionizing
radiation (IR) or cisplatin by abrogating S and G2/M arrest and subsequently promoting
apoptosis. Furthermore, Gö6976 appeared to sensitize NPC xenografts in nude mice to IR or
cisplatin treatment. This is the first report to show that the Chk1 inhibitor Gö6976 sensitizes …
Nasopharyngeal carcinoma (NPC) is a malignant tumor. This type of carcinoma has a low 5-year patient survival rate. Thus, there is a need for improved therapeutics. We determined that the Chk1 inhibitor Gö6976 enhanced the sensitivity of CNE1 and CNE2 cells to ionizing radiation (IR) or cisplatin by abrogating S and G2/M arrest and subsequently promoting apoptosis. Furthermore, Gö6976 appeared to sensitize NPC xenografts in nude mice to IR or cisplatin treatment. This is the first report to show that the Chk1 inhibitor Gö6976 sensitizes NPC cells to treatment using in vitro and in vivo models.
Elsevier